key: cord-1052408-texs178a
authors: Kang, Ji‐Man; Park, Ki‐Sup; Kim, Jong Min; Huh, Hee Jae; Ki, Chang‐Seok; Lee, Nam Yong; Yoo, Keon Hee; Sung, Ki Woong; Koo, Hong‐Hoe; Kim, Yae‐Jean
title: Prospective monitoring of adenovirus infection and type analysis after allogeneic hematopoietic cell transplantation: A single‐center study in Korea
date: 2018-04-10
journal: Transpl Infect Dis
DOI: 10.1111/tid.12885
sha: 20980a79e249fc19586c466e3289ee8a9636a0c8
doc_id: 1052408
cord_uid: texs178a

BACKGROUND: Epidemiologic studies of human adenovirus (HAdV) in allogeneic hematopoietic cell transplantation (HCT) recipients have been conducted mostly in European countries where HAdV 2 (species C) has been most prevalent in the community. The main objective of this study was to investigate the epidemiology and the characteristics of HAdV infection in Korean allogeneic HCT recipients (<19 years). METHODS: In a prospective study from April 2012 to September 2015, HAdV in blood, urine, and stool specimens were monitored weekly from transplantation to day 100 or after if clinically suspected. HAdV infection was defined as positive HAdV PCR result in any specimens regardless of symptoms. RESULTS: A total of 1734 specimens were collected from 57 consecutively enrolled recipients. The cumulative incidence of HAdV infection at day 100, and 1 year was 10%, and 20%, and the incidence of viremia was 2% and 6%, respectively. The median onset time from HCT to viremia was 221 days (range, 7‐596 days). All viremia cases were caused by only HAdV 3 (species B), whereas several types were detected in stool. Among patients with HAdV infection, lower absolute lymphocyte counts and extensive chronic graft‐vs‐host disease were associated with viremia (P = .028 and P = .006, respectively). CONCLUSIONS: Compared to western studies, this study demonstrated a lower incidence and delayed onset of HAdV infections and HAdV 3 was most prevalent in Korea.

in nosocomial and community settings could also occur. 6, 9 HAdVattributable mortality is approximately 1%; however, in disseminated cases, the rate may increase up to 80%-100%. 6, 7, 10 The major risk factor for severe invasive HAdV disease or dissemination is T-cell depletion, including ex vivo T-cell depletion and use of alemtuzumab.

Younger age, unrelated donor graft, cord blood, prolonged immunosuppressive treatment, and an absolute lymphocyte count (ALC) <300/μL are additional risk factors. 2, 6, 7, 11, 12 With this background, the 4th European Society of Infectious Diseases in Leukemia (ECIL-4) recommended routine HAdV monitoring using quantitative polymerase chain reaction (PCR) in peripheral blood, especially in high-risk patients. 7 However, the correlation between HAdV species and clinical features in immunocompromised population has not been established yet. HAdVs cause a variety of clinical manifestations depending on virus type and tissue tropism in immunocompetent host. For example, species B:1, C, and E can cause respiratory illness, whereas species F and G can mainly cause gastroenteritis. Species B:2 (eg HAdV 11, 34, and 35) are responsible for urinary tract infection, and species B and D are known to be associated with keratoconjunctivitis. 13, 14 Serious complications often result from lower respiratory tract illness, particularly in association with HAdV 3, 7, and 21 (all 3 species B). 15, 16 We hypothesized HAdV types could also affect the clinical features including the severity and/or dissemination in allogeneic HCT recipients. The main objectives of this study were to investigate the epidemiology of HAdV infections and the clinical correlations of HAdV types among Korean pediatric allogeneic HCT recipients. In addition, we explored potential risk factors for HAdV infection and/ or viremia and HAdV-attributable mortality.

This study was conducted at Samsung Medical Center (SMC), Seoul, Korea, from 1 April 2012 to 30 September 2015. All consecutive pediatric recipients aged less than 19 years who received allogeneic HCT at the pediatric cancer center and agreed to participate were included. Informed consent and assent were obtained at the time of enrollment. This study was approved by the institutional review board (IRB) of SMC (IRB #2011-11-066-010).

Recipients were screened for respiratory virus infection before the admission for HCT in our center. In enrolled patients, blood, urine, and stool specimens were collected prospectively from the infusion date of transplantation to day 100. About 1 mL of EDTA whole blood was collected weekly from the day of transplantation (day 0, day 7, day 14, etc.). Urine and stool samples were collected weekly as well as blood samples. These collected specimens were stored at −80°C until DNA extraction. After day 100, urine and stool specimens were further tested whenever clinically suspected. If

HAdV was detected, we performed additional quantitative real-time PCR using blood specimens to detect HAdV viremia. Respiratory specimens were tested using multiplex respiratory virus PCR (LG Life Science, Korea) if respiratory symptoms were present as a part of routine care practice.

DNA was extracted from 200 μL aliquots of clinical samples using the QIAamp Blood or Stool Mini Kit (QIAGEN, Hilden, Germany). Eluted DNA was stored at −20°C until PCR amplification. Quantitative real-time PCR was used to detect HAdV in blood specimens using a commercial Adenovirus R-Gene ® kit (Argene, Varhilles, France). 17 The lower limit for quantitation was 200 copies/mL. Qualitative conventional PCR was performed to detect HAdV in urine and stool specimens using a premix kit (Bioneer, Daejeon, Korea) following the manufacturer's protocol.

Human adenovirus type was determined by sequencing hyper-variable region 1-6 of the hexon gene. Nested PCR was performed to secure sufficient HAdV DNA for sequencing, using a previously described method with minor modifications (Method S1). 18 Sequencing was performed in both directions using the 2nd round PCR primers. Sequencher™ 4.9 software (Gene Codes, Ann Arbor, MI, USA) and Basic Local Alignment Search Tool (BLAST) software (http://blast.ncbi.nlm.nih.gov/) were used to identify HAdV types. Phylogenetic and molecular analyses were conducted using MEGA 6.06. Reference HAdV strains are shown in Table S1 .

Epidemiologic data and patient characteristics including age at HCT, sex, underlying disease, type of donor, source of graft, use of total body irradiation (TBI), use of anti-thymoglobulin (ATG), and conditioning regimen were collected from medical records at the time of enrollment. We performed weekly monitoring of the clinical data including symptoms, laboratory data, the severity of graft-vs-host 

Demographic and clinical data were compared using Fisher's exact test or chi-square test for categorical variables and the Mann-Whitney U test for continuous variables, as appropriate.

Categorical variables were presented as frequencies (percentages) and continuous variables were summarized as medians (ranges). Logistic regression analysis was performed to evaluate the risk factors for HAdV infection or viremia. The relationships between potential risk factors and outcomes were tested by Cox proportional-hazards regression. Variables with P < .1 in the univariate analysis were included in the multivariate analysis (model I). We also included other variables: age at HCT, sex, relapsed status of underlying disease (relapsed or not), and severe acute GVHD (grade ≥3) in additional multivariate analysis (model II). A phylogenetic tree was generated using the neighbor-joining 

Between April 2012 and September 2015, a total of 93 pediatric recipients received 97 allogeneic HCTs at SMC. Among them, 57 recipients (61%) with 58 HCT procedures were enrolled ( Figure S1 ).

Median age at HCT was 5.2 years (range, 0.6-18.1 years) and 36 recipients (62%) were male. Median follow-up was 2.1 years (range 0.2-4.1 years). None of our patients received ex vivo T-cell depletion. Other detailed characteristics are listed in Table 1 .

A total of 819 blood samples, 452 stool samples, and 463 urine samples were tested, and HAdV was detected in 16 samples from 12 recipients ( Table 2 ). The cumulative incidence of HAdV infection at day 100, 1 year, and 2 years were 10% (95% confidence interval [CI], 6.4%-14.4%), 20% (95% CI, 14.9%-25.9%) and 23% (95% CI, 17.0%-28.8%), respectively ( Figure 1 ). Four recipients developed HAdV viremia and the cumulative incidences at day 100, 1, and 2 years were 2% (95% CI, 0.0-3.4%), 6% (95% CI, 3.2%-8.2%) and 8% (95% CI, 4.3%-12.3%), respectively ( Figure 1 ). Median time from HCT to first HAdV infection was 113 days (range, 7-596 days) and to onset of HAdV viremia was 221 days (range, 7-596 days). More than half of HAdV infections (58%, 7/12) occurred after day 100 from HCT. All of HAdV-positive respiratory specimens (n = 5) were detected after day 100 (Table 3 ).

Among the 12 HAdV-infected patients, 7 (58%, 7/12) experienced a relapse of their underlying diseases. One patient (recipient 038) had 2 separate episodes of HAdV infection; this patient developed HAdV diarrhea without viremia at day 53 after the 1st HCT, and developed another episode of HAdV infection (HAdV detected in urine and blood) at day 7 and 16 after the 2nd HCT which was performed more than 1 year after the 1st HCT. Ten of 12 HAdV infections were probable HAdV diseases and 2 were asymptomatic infections. Enteritis with diarrhea or melena (n = 4), and respiratory illness (n = 4) were the most common clinical manifestations, followed by hematuria (n = 2) and asymptomatic condition (n = 2) ( Table 3) . 

Among the total of 16 HAdV-detected samples, 15 samples were available for type sequencing and 12 representative samples were studied ( Table 2 ). Among them, HAdV 3 was the most commonly detected type (n = 5), followed by HAdV 1 (n = 3). There was only one case for HAdV 2, 31, 35, and 41, respectively (Table 3) . A phylogenetic tree for those 12 HAdV is shown in Figure S2A .

In typing analysis, HAdV 3 was the only type detected in blood, while various types were detected in stool (HAdV 1, 2, 3, 31 and 41) (P = .029). One urine specimen was typed as HAdV 35 (Table 2) .

Of note, different types of HAdV were detected sequentially in the same recipient in 2 cases (Figure 2 ). In one patient (recipient 016), HAdV 3 was detected in blood (day 270) and HAdV 1 was detected in stool (day 278). In another patient (recipient 059), HAdV 31 was detected on day 50 and HAdV 1 was detected on day 56 in stool samples ( Figure S2B ).

The univariate analysis did not identify potential risk factors for HAdV infection (Table S2 ). In cases of HAdV viremia (n = 3), extensive chronic GVHD was identified as a risk factor by univariate analysis (P = .013); however, we were unable to apply multivariate analysis due to the small number of cases (Table S3 ).

In the univariate analysis, category of underlying disease, relapsed state of underlying disease, type of donor, intensity of conditioning regimen, use of ATG, extensive chronic GVHD, and existence of HAdV viremia were identified as potential risk factors for mortality (P < .1). HAdV viremia appeared to be a significant risk factor for mortality in univariate analysis (P = .045), but was not significant in multivariate analysis ( The results of this study highlight 2 epidemiologic findings that are different from those of previous studies. First, the cumulative incidence of HAdV viremia was lower than those of previous studies. In this study, the cumulative incidences of HAdV viremia at day 100 and 1 year were 2% and 6%, whereas the rates reported in previous studies were 6%-50% in pediatric patients. 7, 8, 19, 20 One possible explanation is the use of alemtuzumab or ex vivo T-cell This recipient was admitted to the hospital due to anemia and developed fever during red blood cell transfusion. Respiratory multiplex PCR was performed as a routine care practice. and species A (HAdV 31) were the most prevalent species among pediatric HCT recipients. 3, 8, 19 In community infection settings, HAdV 2, 1, and 3 were identified as the most prevalent genotypes in the UK and Croatia, whereas HAdV 3 (37%), 7 (23%), and 2 (11%)

were identified as the prevalent types in Korea. 13, 25 The results of type analyses in East Asian countries such as Taiwan and Japan also showed that species B (especially HAdV 3) was most prevalent in the community. 13, 14, 26 HAdV C is well known for persistent infection in mucosal lymphocytes and tissues. Hence, HAdV C may be more likely to be in latent state before transplantation which can be linked to early post-HCT reactivation. Difference in the prevalence of specific virus types in the community might be one of possible explanations why the incidence of HAdV infection in our study is lower than those of previous studies in European countries. 27, 28 The high HAdV loads in blood have known to be an important risk factor for the disease severity and mortality. Therefore, the ECIL-4 guidelines recommended quantitative PCR monitoring of HAdV in peripheral blood. 7 Lion et al 19, 24 reported that most fatal cases were associated with species C among 132 Austrian pediatric allogeneic HCT recipients.

The relationship between HAdV types and clinical severity and/or dissemination remains uncertain, based on current data. Hence, further studies are needed.

We observed interesting findings in virus-type analyses. First, different types of HAdV were detected in the same recipient within a short time interval (recipient 059) ( Figure S2B) high. Major reasons for refusal at enrollment and poor compliance included difficulty in collecting and delivering urine and stool specimens. Second, there is a possibility that we underestimated the incidence of HAdV infection and viremia due to the fact that routine surveillance was performed only until day 100 after HCT, because we found that significant numbers of HAdV infections occurred post-HCT day 100. Lastly, the size of our study sample was relatively small to demonstrate definite risk factors for HAdV infection or viremia.

In summary, we observed lower incidence rate and more delayed onset pattern of HAdV infections than those of previous studies, which might be influenced by extent of T-cell depletion and/or local HAdV epidemiology. HAdV 3 was the most common type, followed by HAdV 1, whereas HAdV 2 had been reported as the most prevalent type in western countries. Although we were unable to identify potential risk factors for HAdV infection or viremia, we found that HAdV-infected recipients with viremia were more likely to have extensive chronic GVHD and lower lymphocyte counts than those without viremia.

In conclusion, this study demonstrated the distinct epidemiology of HAdV in Korean recipients. Watchful monitoring for HAdV viremia is recommended in HAdV-infected HCT recipients, particularly in those with severe lymphopenia or extensive chronic GVHD.

Additional studies are necessary to clarify the relationships between HAdV type and clinical severity or rate of viremia.

The authors of this report have no conflicts of interest to disclose. 

Adenoviral infection in hematopoietic stem cell transplantation: early diagnosis with quantitative detection of the viral genome in serum and urine

Detection of adenovirusspecific T cells in children with adenovirus infection after allogeneic stem cell transplantation

Adenovirus infection and disease in paediatric haematopoietic stem cell transplant patients: clues for antiviral pre-emptive treatment

Evaluation of a surveillance strategy for early detection of adenovirus by PCR of peripheral blood in hematopoietic SCT recipients: incidence and outcome

Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery

Adenovirus infections in immunocompetent and immunocompromised patients

European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4

Patient, virus, and treatment-related risk factors in pediatric adenovirus infection after stem cell transplantation: results of a routine monitoring program

Prolonged outbreak of adenovirus A31 in allogeneic stem cell transplant recipients

High lethality of human adenovirus disease in adult allogeneic stem cell transplant recipients with high adenoviral blood load

How I treat adenovirus in hematopoietic stem cell transplant recipients

Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience

Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention

Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture

A human adenovirus species B subtype 21a associated with severe pneumonia

Genome type analysis of adenovirus types 3 and 7 isolated during successive outbreaks of lower respiratory tract infections in children

Comparison of in-house real-time quantitative PCR to the Adenovirus R-Gene kit for determination of adenovirus load in clinical samples

Molecular typing of human adenoviruses by PCR and sequencing of a partial region of the hexon gene

Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation

Risk factors for molecular detection of adenovirus in pediatric hematopoietic stem cell transplantation recipients

The current role of T cell depletion in paediatric stem cell transplantation

Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation

Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation

Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease

Adenovirus respiratory infections in hospitalized children: clinical findings in relation to species and serotypes

Molecular characterization of human adenovirus infection in Thailand

Latent species C adenoviruses in human tonsil tissues

Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients

Sequential emergence of multiple adenovirus serotypes after pediatric stem cell transplantation

Disseminated adenovirus disease by multiple adenovirus serotypes following allogeneic hematopoietic stem cell transplantation

MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study

Prospective monitoring of adenovirus infection and type analysis after allogeneic hematopoietic cell transplantation: A single-center study in Korea